Navigation Links
RI Hospital researchers discover new strategy to effectively treat, prevent osteoarthritis

PROVIDENCE, R.I. Think new discoveries are the bee's knees? This one is even better -- this research out of Rhode Island Hospital is the mice's knees. Researchers have found that adding lubricin, a protein that our bodies naturally produce, to the fluid in our joints may reduce the risk of or even prevent osteoarthritis (OA). The findings, in a paper by Gregory D. Jay, M.D., Ph.D., of the department of emergency medicine, is published online in advance of print in the journal Proceedings of the National Academy of Sciences.

The discoveries were made in part by studying the knees of mice, which genetically lack lubricin, causing an aggressive arthritis in spite of high levels of hyaluronic acid in the synovial fluid. A lack of lubricin, resulting in higher friction, leads to cartilage cell death - even in the presence of high levels of hyaluronic acid, a viscous fluid that cushions the joints. This discovery appears to challenge the practice of injecting hyaluronic acid alone into a patient's joints.

"The lubricant is a protein, not hyaluronic acid, and currently, there are no disease-modifying treatments for osteoarthritis," Jay said. "Patients suffering from this degenerative joint disease either go through a total joint replacement, or are forced to live with pain every day. This discovery, however, supports that adding a lubricin replacement to the fluid in joints may in fact prevent osteoarthritis in those who have a genetic predisposition to the illness, or who have suffered significant trauma to the joints."

Jay added, "We are working to create a replacement for natural lubricin that we hope will significantly improve the treatment options, and ultimately prevention measures, for those with early osteoarthritis, or those with joint injuries."

OA, the most common form of arthritis, is a painful joint disease that can place severe limits on daily activity and quality of life. It causes pain, swelling and reduced motion in the joints, and while it can occur in any joint, it is most common in the hands, knees, hips or spine. The prevalence of OA increases beginning at age 45, according to the Centers for Disease Control and Prevention, and affects 27 million adults in the U.S. Risk factors include obesity, aging and injury/trauma to a joint.

"While many Baby Boomers are living longer, more active lives, obesity is a major problem in our country for many age groups," Jay said. "Both excessive weight, and injury to the joints can lead to osteoarthritis, which results in a more sedentary lifestyle. This discovery supports our ongoing efforts to produce a new therapy to protect cartilage among those with a transient loss of that protection, which places the cartilage at risk."


Contact: Ellen Slingsby

Related biology technology :

1. World Kidney Day Symposium at Allegheny General Hospital Brings Attention to Disease that Afflicts 26 Million People in U.S.
2. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
3. Infants Protected with New Security Solution at Danbury Hospital
4. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
5. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
6. University of College London Hospitals (UCLH) Selects GEO SCAN Medical as New Standard of Care for the Detection and Treatment of Prostate Cancer
7. Moscow State University Hospital Selects Ekahau RTLS to Improve Operations and Patient Safety
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Boston Childrens Hospital announces international genomics competition winner
10. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
11. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
Post Your Comments:
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):